These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 12840709)

  • 21. Cellular HIV-1 DNA quantitation in patients during simplification therapy with protease inhibitor-sparing regimens.
    Sarmati L; Parisi SG; Nicastri E; d'Ettorre G; Andreoni C; Dori L; Gatti F; Montano M; Buonomini AR; Boldrin C; Palù G; Vullo V; Andreoni M
    J Med Virol; 2007 Jul; 79(7):880-6. PubMed ID: 17516532
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Darunavir: after multiple antiretroviral treatment failure: another option.
    Prescrire Int; 2008 Jun; 17(95):109. PubMed ID: 18629967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selected metabolic and morphologic complications associated with highly active antiretroviral therapy.
    Smith KY
    J Infect Dis; 2002 May; 185 Suppl 2():S123-7. PubMed ID: 12001033
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Antiretroviral treatment for HIV infection. Where we are and where we are going?].
    Sierra-Madero JG; Franco-San-Sebastián D
    Rev Invest Clin; 2004; 56(2):222-31. PubMed ID: 15377075
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adherence to antiretroviral therapy: the more you look, the more you see.
    Taiwo B
    Curr Opin HIV AIDS; 2009 Nov; 4(6):488-92. PubMed ID: 20048715
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Once-daily dosing of nevirapine in HAART.
    Clotet B
    J Antimicrob Chemother; 2008 Jan; 61(1):13-6. PubMed ID: 18006524
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of a pill-swallowing training intervention to improve antiretroviral medication adherence in pediatric patients with HIV/AIDS.
    Garvie PA; Lensing S; Rai SN
    Pediatrics; 2007 Apr; 119(4):e893-9. PubMed ID: 17353298
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study.
    Røge BT; Barfod TS; Kirk O; Katzenstein TL; Obel N; Nielsen H; Pedersen C; Mathiesen LR; Lundgren JD; Gerstoft J
    HIV Med; 2004 Sep; 5(5):344-51. PubMed ID: 15369509
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term efficacy and safety of protease inhibitor switching to nevirapine in HIV-infected patients with undetectable virus load.
    Gil P; de Górgolas M; Estrada V; Arranz A; Rivas P; Yera C; García R; Granizo JJ; Fernández-Guerrero M
    Clin Infect Dis; 2004 Oct; 39(7):1024-9. PubMed ID: 15472856
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regimen-dependent variations in adherence to therapy and virological suppression in patients initiating protease inhibitor-based highly active antiretroviral therapy.
    Moore DM; Hogg RS; Yip B; Wood E; Harris M; Montaner JS
    HIV Med; 2006 Jul; 7(5):311-6. PubMed ID: 16945076
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A 6-month interruption of antiretroviral therapy improves adipose tissue function in HIV-infected patients: the ANRS EP29 Lipostop Study.
    Kim MJ; Leclercq P; Lanoy E; Cervera P; Antuna-Puente B; Maachi M; Dorofeev E; Slama L; Valantin MA; Costagliola D; Lombes A; Bastard JP; Capeau J
    Antivir Ther; 2007; 12(8):1273-83. PubMed ID: 18240867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
    Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
    HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
    Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E;
    Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical benefit of interventions driven by therapeutic drug monitoring.
    Rendón A; Núñez M; Jiménez-Nácher I; González de Requena D; González-Lahoz J; Soriano V
    HIV Med; 2005 Sep; 6(5):360-5. PubMed ID: 16156885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Update on antiretroviral therapy.
    Riordan A; Bugembe T
    Arch Dis Child; 2009 Jan; 94(1):70-4. PubMed ID: 18838416
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited.
    Orrell C; Harling G; Lawn SD; Kaplan R; McNally M; Bekker LG; Wood R
    Antivir Ther; 2007; 12(1):83-8. PubMed ID: 17503751
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The rise and fall of triple nucleoside reverse transcriptase inhibitor (NRTI) regimens.
    Arribas JR
    J Antimicrob Chemother; 2004 Sep; 54(3):587-92. PubMed ID: 15282236
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adherence to HIV drug therapy.
    Gross R
    LDI Issue Brief; 2002 Nov; 8(3):1-4. PubMed ID: 12530426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. What does the generalist need to know about HIV infection?
    Gallant JE
    Adv Chronic Kidney Dis; 2010 Jan; 17(1):5-18. PubMed ID: 20005484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.